Just In
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.

pharma industry

(8 search results)

Nandini Piramal charts bold growth path: Piramal Pharma eyes $2 billion revenue by FY30
Innovation-led Indian healthcare market to hit $320 bn by FY28: Bain
Laurus Injects Tech In Pharma

Laurus Injects Tech In Pharma

Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
Surprise! Despite Covid-19 sales, Indian pharma an underperformer
Sluggish exports to hit pharma revenue growth: CRISIL
Predictions 2022: Year of personalisation of healthcare and therapies
Predictions 2022: The pandemic and beyond: How the pharma industry is shaping up for the future